SCHEMBL2786888

SCHEMBL2786888

O=C(Nc1nc2cc(C(F)(F)F)cc(NC3CC3)n2n1)c1ccc(N2CCN(C(=O)O)CC2)nc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAP3K5 Q99683 1/20 0.66
▸ SMN1; SMN2 Q16637 4/20 0.42
▸ LMNA P02545 4/20 0.41
▸ KMT2A Q03164 3/20 0.41
▸ HTT P42858 3/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ MAPT P10636 3/20 0.41
▸ STAT3 P40763 1/20 0.40
▸ JAK2 O60674 2/20 0.39
▸ JAK1 P23458 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ MGLL Q99685 1/20 0.39
▸ HPGDS O60760 2/20 0.39
▸ SCD O00767 1/20 0.38
▸ MPL P40238 1/20 0.37
▸ TRPV1 Q8NER1 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2788851 0.93 MAP3K5 (0.69) MAP3K5SMN1; SMN2LMNAKMT2AHTT
SCHEMBL2789544 0.91 MAP3K5 (0.67) MAP3K5SMN1; SMN2LMNAKMT2AHTT
SCHEMBL2789598 0.90 MAP3K5 (0.66) MAP3K5SMN1; SMN2LMNAHTTALDH1A1
SCHEMBL2787681 0.90 MAP3K5 (0.66) MAP3K5SMN1; SMN2KMT2AMAPTSTAT3
SCHEMBL3020469 0.89 MAP3K5 (0.60) MAP3K5SMN1; SMN2LMNAKMT2AHTT
SCHEMBL2787410 0.84 MAP3K5 (0.76) MAP3K5KMT2AJAK2JAK1
SCHEMBL2789285 0.83 JAK1 (0.49) MAP3K5JAK2JAK1
SCHEMBL3024342 0.82 MAP3K5 (0.71) MAP3K5JAK2JAK1HPGDS
SCHEMBL2788575 0.80 MAP3K5 (1.00) MAP3K5SMN1; SMN2LMNAKMT2AHTT
SCHEMBL2788032 0.78 MAP3K5 (0.65) MAP3K5JAK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2181112-A1 TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS Merck Serono S.A. (CH) 2010-05-05 — — EP claimed
WO-2009027283-A1 TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS MERCK SERONO S.A. (CH) 2009-03-05 — — WO claimed
US-20100197681-A1 Triazolopyridine Compounds and Their Use as Ask Inhibitors MERCK SERONO SA (CH) 2010-08-05 — — US disclosed
EP-2181112-A1 TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS Merck Serono S.A. (CH) 2010-05-05 — — EP disclosed
WO-2009027283-A1 TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS MERCK SERONO S.A. (CH) 2009-03-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197681-A1 Triazolopyridine Compounds and Their Use as Ask Inhibitors MAP3K5, MAPKAPK5, MAP3K9 MAP3K5 1/4885SMN1; SMN2 3001/4885LMNA 4032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback